ArticleJournal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance2026
Characteristics and clinical significance of myocardial work in cardiac light-chain amyloidosis: pressure-volume loop analysis based on cardiovascular magnetic resonance.
Article in Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Myocardial work in light-chain and transthyretin-related amyloidosis with preserved ejection fraction: a cardiovascular magnetic resonance study.Insights into imaging · 2026Article
- Refining Risk Stratification in Light-Chain Cardiac Amyloidosis: A Single-Center Ambispective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeft ventricular pressure-volume (PV) loop analysis via cardiovascular magnetic resonance (CMR) offers noninvasive assessment of cardiac thermodynamic efficiency. We aimed to evaluate the clinical relevance and prognostic value of noninvasive PV-loop parameters in patients with cardiac light-chain (AL) amyloidosis.
methodsThis prospective, single-center study enrolled patients with cardiac AL amyloidosis (AL-CA) who underwent CMR between November 2011 and September 2023. PV-loop parameters were derived from CMR cine images and brachial blood pressure. The primary endpoint was all-cause mortality. Cox regression analysis assessed associations between PV-loop parameters and outcomes, with incremental prognostic value evaluated using C-statistics and likelihood ratio tests.
resultsThe single-center, prospective study included 267 consecutive AL-CA patients (mean age, 58.8 ± 9.8 years; male/female, 168/99) and 30 healthy controls with similar age and sex (mean age, 59.9 ± 8.2 years; male/female, 15/15). Work efficiency (WE) showed moderate to strong correlations with cardiac function, volumes, decreased activity, and amyloid burden (all P < 0.05). During a median follow-up of 42 months (interquartile range: 35-49), the all-cause mortality rate was 69.3% (185/267). Univariable Cox analysis showed AL-CA patients with WE <72.2% were at higher mortality risk (hazard ratio 2.45, 95% confidence interval: 1.68-3.57; P < 0.001). After multivariable adjustment, WE <72.2% remained an independent prognostic factor. The integration of WE with Mayo 2004 stage enhanced prognostic discrimination and calibration (C-statistic 0.65, χ² 36.28) relative to Mayo 2004 stage alone (C-statistic 0.58, χ² 25.79), and performed comparably to the combination of extracellular volume (ECV) fraction with Mayo 2004 stage (C-statistic 0.66, χ² 44.49).
conclusionMyocardial work impairment can be detected early, even with preserved left ventricular ejection fraction. WE derived from noninvasive and non-enhanced PV-loop analysis via CMR, not only reflects disease severity as quantified by ECV, but also serves as an alternative marker to ECV in risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.